Diagnosis and Treatment of Patients With Secondary Hyperparathyroidism and Renal Insufficiency. Therapeutic Potential of Paricalcitol

Белая, Ж. Е.; Рожинская, Л. Я.

doi:10.21518/2079-701x-2017-20-151-156

Med. sov.

2017

DOI: 10.21518/2079-701x-2017-20-151-156

|View full text |Cite

Diagnosis and Treatment of Patients With Secondary Hyperparathyroidism and Renal Insufficiency. Therapeutic Potential of Paricalcitol

Ж. Е. Белая¹,

Л. Я. Рожинская²

Abstract: Уменьшение массы действующих нефронов при хро-нической почечной недостаточности (ХПН) ведет к гипер-фосфатемии, сопровождающейся реципрокным снижени-

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Saprina,

Zhulina,

Zhulin

et al. 2023

SJCEM

View full text Add to dashboard Cite

There is a universal trend towards increase of patients with chronic kidney disease by 7% on average. In the Russian Federation, the annual increase is even higher, at about 10%. The average age of patients receiving renal replacement therapy is 60 years in the Tomsk region and 56 years in Russia, which is relatively lower than in European countries and the United States. With increasing age of patients receiving dialysis treatment, a progressive increase in the incidence of secondary hyperparathyroidism is recorded. Mineral and bone disorders, hyperphosphatemia, hypercalcemia all lead to premature vascular calcification, increase the risk of cardiovascular complications and death. At the same time, elderly patients are characterized by an increase in risks immediately after the start of dialysis therapy. There is a global tendency towards increase in the target level of parathyroid hormone. Parathyroidectomy is recognized as a gold standard for treatment of drug-resistant hyperparathyroidism across the world. As the development of hyperplasia in the parathyroid glands does not proceed synchronously, instead progressing at different rates and in the selective glands, methods of local influence on the altered glands have recently been developed in order to gradually control secondary hyperparathyroidism. Alternative to the total parathyroidectomy are minimally invasive non-surgical methods, attractive due to a smaller number of complications, such as bleeding and paresis of the recurrent laryngeal nerve. Examples of minimally invasive methods are local injections of preparations of the active form of vitamin D, which lead to apoptosis of parathyroid gland cells instead of their destruction, and are safer in relation to surrounding tissues. This article presents current data on the prevalence of secondary hyperparathyroidism in chronic kidney disease. An analysis of clinical trials was carried out based on articles indexed in the Scopus database, the Russian Science Citation Index, PubMed and Web of Science.

show abstract

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Saprina,

Zhulina,

Zhulin

et al. 2023

SJCEM

View full text Add to dashboard Cite

show abstract

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Saprina,

Zhulina,

Zhulin

et al. 2023

SJCEM

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Diagnosis and Treatment of Patients With Secondary Hyperparathyroidism and Renal Insufficiency. Therapeutic Potential of Paricalcitol

Abstract: Уменьшение массы действующих нефронов при хро-нической почечной недостаточности (ХПН) ведет к гипер-фосфатемии, сопровождающейся реципрокным снижени-

Cited by 2 publications

References 23 publications

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Prevalence and current approaches to the treatment of secondary hyperparathyroidism and its complications in chronic kidney disease: a literature review

Contact Info

Product

Resources

About